A novel lactococcal vaccine expressing a peptide from the m2 antigen of h5n2 highly pathogenic avian influenza a virus prolongs survival of vaccinated chickens

Veterinary Medicine International

Volumn 2013, Issue , 2013, Pages

  Reese, Kaleb A ^a   Lupfer, Christopher ^a,b   Johnson, Rudd C ^a   Mitev, Georgi M ^a   Mullen, Valerie M ^a   Geller, Bruce L ^a   Pastey, Manoj ^a  

^a OREGON STATE UNIVERSITY   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVES; AVIAN INFLUENZA VIRUS; BACTERIA (MICROORGANISMS); GALLUS GALLUS; INFLUENZA A VIRUS; INFLUENZAVIRUS A; LACTOCOCCUS LACTIS;

EID: 84878730593     PISSN: None     EISSN: 20420048     Source Type: Journal    
DOI: 10.1155/2013/316926     Document Type: Article

References (52)

1. USDA Economic Research Service,. 2012, http://www.ers.usda.gov/
2. US Poultry and Egg Association,. 2012, http://www.uspoultry.org/economic- data/
3. Londt B. Z., Banks J., Alexander D. J., Highly pathogenic avian influenza viruses with low virulence for chickens in in vivo tests. Avian Pathology 2007 36 5 347 350 2-s2.0-34848903534 10.1080/03079450701589134 (Pubitemid 47509228)
4. Bermúdez-Humarán L. G., Cortes-Perez N. G., Lefèvre F., Guimarães V., Rabot S., Alcocer-Gonzalez J. M., Gratàdoux J. J., Rodriguez-Padilla C., Tamez-Guerra R. S., Corthier G., Gruss A., Langella P., A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. Journal of Immunology 2005 175 11 7297 7302 2-s2.0-28244455880 (Pubitemid 41713425)
5. Chamberlain L., Wells J. M., Robinson K., Schofield K., LePage R., Pozzi G., Wells J. M., Mucosal immunization with recombinant Lactococcus lactis. Gram-Positive Bacteria as Vaccine Vehicles for Mucosal Immunization 1997 Austin, Tex, USA Landes Bioscience 83 106
6. Dieye Y., Hoekman A. J. W., Clier F., Juillard V., Boot H. J., Piard J. C., Ability of Lactococcus lactis to export viral capsid antigens: a crucial step for development of live vaccines. Applied and Environmental Microbiology 2003 69 12 7281 7288 2-s2.0-2142805217 10.1128/AEM.69.12.7281-7288.2003 (Pubitemid 38585380)
7. Enouf V., Langella P., Commissaire J., Cohen J., Corthier G., Bovine rotavirus nonstructural protein 4 produced by Lactococcus lactis is antigenic and immunogenic. Applied and Environmental Microbiology 2001 67 4 1423 1428 2-s2.0-0035316823 10.1128/AEM.67.4.1423-1428.2001 (Pubitemid 33644904)
8. Geller B. L., Wade N., Gilberts T. D., Hruby D. E., Johanson R., Topisirovic L., Surface expression of the conserved C repeat region of streptococcal M6 protein within the Pip bacteriophage receptor of Lactococcus lactis. Applied and Environmental Microbiology 2001 67 12 5370 5376 2-s2.0-0035653732 10.1128/AEM.67.12.5370-5376.2001 (Pubitemid 33640964)
9. Lee M. H., Roussel Y., Wilks M., Tabaqchali S., Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice. Vaccine 2001 19 28-29 3927 3935 2-s2.0-0035898938 10.1016/S0264-410X(01)00119-0 (Pubitemid 32566316)
10. Pei H., Liu J., Cheng Y., Sun C., Wang C., Lu Y., Ding J., Zhou J., Xiang H., Expression of SARS-coronavirus nucleocapsid protein in Escherichia coli and Lactococcus lactis for serodiagnosis and mucosal vaccination. Applied Microbiology and Biotechnology 2005 68 2 220 227 2-s2.0-21744434973 10.1007/s00253-004-1869-y (Pubitemid 41110944)
11. Perez C. A., Eichwald C., Burrone O., de Mendoza D., Rotavirus vp7 antigen produced by Lactococcus lactis induces neutralizing antibodies in mice. Journal of Applied Microbiology 2005 99 5 1158 1164 2-s2.0-27444433722 10.1111/j.1365-2672.2005.02709.x (Pubitemid 41531306)
12. Xin K. Q., Hoshino Y., Toda Y., Igimi S., Kojima Y., Jounai N., Ohba K., Kushiro A., Kiwaki M., Hamajima K., Klinman D., Okuda K., Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. Blood 2003 102 1 223 228 2-s2.0-0038644449 10.1182/blood-2003-01-0110 (Pubitemid 36759658)
13. Lei H., Xu Y., Chen J., Wei X., Lam D. M. K., Immunoprotection against influenza H5N1 virus by oral administration of enteric-coated recombinant Lactococcus lactis mini-capsules. Virology 2010 407 2 319 324 2-s2.0-77957673456 10.1016/j.virol.2010.08.007
14. Mannam P., Jones K. F., Geller B. L., Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infection and Immunity 2004 72 6 3444 3450 2-s2.0-2542622189 10.1128/IAI.72.6.3444-3450.2004 (Pubitemid 38697770)
15. Zou P., Liu W., Chen Y. H., The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection. International Immunopharmacology 2005 5 4 631 635 2-s2.0-13844275100 10.1016/j.intimp.2004.12.005 (Pubitemid 40248318)
16. Corthier G., Delorme C., Ehrlich S. D., Renault P., Use of luciferase genes as biosensors to study bacterial physiology in the digestive tract. Applied and Environmental Microbiology 1998 64 7 2721 2722 2-s2.0-0031867040 (Pubitemid 28303326)
17. Drouault S., Corthier G., Ehrlich S. D., Renault P., Survival, physiology, and lysis of Lactococcus lactis in the digestive tract. Applied and Environmental Microbiology 1999 65 11 4881 4886 2-s2.0-0032729983
18. Klijn N., Weerkamp A. H., de Vos W. M., Genetic marking of Lactococcus lactis shows its survival in the human gastrointestinal tract. Applied and Environmental Microbiology 1995 61 7 2771 2774 2-s2.0-0029063557
19. Vesa T., Pochart P., Marteau P., Pharmacokinetics of Lactobacillus plantarum NCIMB 8826, Lactobacillus fermentum KLD, and Lactococcus lactis MG 1363 in the human gastrointestinal tract. Alimentary Pharmacology and Therapeutics 2000 14 6 823 828 2-s2.0-0034040407 10.1046/j.1365-2036.2000.00763. x (Pubitemid 30352751)
20. Bermúdez-Humarán L. G., Langella P., Miyoshi A., Gruss A., Tamez Guerra R., Montes de Oca-Luna R., Le Loir Y., Production of human papillomavirus type 16 E7 protein in Lactococcus lactis. Applied and Environmental Microbiology 2002 68 2 917 922 2-s2.0-0036156789 10.1128/AEM.68.2.917-922.2002 (Pubitemid 34113085)
21. Czerwiński J., Højberg O., Smulikowska S., Engberg R. M., Mieczkowska A., Influence of dietary peas and organic acids and probiotic supplementation on performance and caecal microbial ecology of broiler chickens. British Poultry Science 2010 51 2 258 269 2-s2.0-77952520242 10.1080/00071661003777003
22. Olsen K. N., Henriksen M., Bisgaard M., Nielsen O. L., Christensen H., Investigation of chicken intestinal bacterial communities by 16S rRNA targeted fluorescence in situ hybridization. Antonie van Leeuwenhoek 2008 94 3 423 437 2-s2.0-50849102622 10.1007/s10482-008-9260-0
23. Feng J., Zhang M., Mozdzanowska K., Zharikova D., Hoff H., Wunner W., Couch R. B., Gerhard W., Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virology Journal 2006 3 102 113 2-s2.0-33845618007 10.1186/1743-422X-3-102 (Pubitemid 44953692)
24. Johansson B. E., Moran T. M., Bona C. A., Popple S. W., Kilbourne E. D., Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin: II. Sequential infection of mice simulates human experience. Journal of Immunology 1987 139 6 2010 2014 2-s2.0-0023280692 (Pubitemid 17141638)
25. Liu W., Li H., Chen Y. H., N -terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunology and Medical Microbiology 2003 35 2 141 146 2-s2.0-0037456637 10.1016/S0928-8244(03)00009-9 (Pubitemid 36298936)
26. Schotsaert M., de Filette M., Fiers W., Saelens X., Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Review of Vaccines 2009 8 4 499 508 2-s2.0-65449185906 10.1586/erv.09.6
27. Babapoor S., Neef T., Mittelholzer C., Girshick T., Garmendia A., Shang H., Khan M. I., Burkhard P., A novel vaccine using nanoparticle platform to present immunogenic M2e against avian influenza infection. Influenza Research and Treatment 2011 2011 12 10.1155/2011/126794 126794
28. de Filette M., Jou W. M., Birkett A., Lyons K., Schultz B., Tonkyro A., Resch S., Fiers W., Universal influenza A vaccine: optimization of M2-based constructs. Virology 2005 337 1 149 161 2-s2.0-19444368726 10.1016/j.virol.2005. 04.004 (Pubitemid 40725448)
29. Fan J., Liang X., Horton M. S., Perry H. C., Citron M. P., Heidecker G. J., Fu T. M., Joyce J., Przysiecki C. T., Keller P. M., Garsky V. M., Ionescu R., Rippeon Y., Shi L., Chastain M. A., Condra J. H., Davies M. E., Liao J., Emini E. A., Shiver J. W., Preclinical study of influenza virus a M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004 22 23-24 2993 3003 2-s2.0-3843069907 10.1016/j.vaccine.2004.02.021 (Pubitemid 39037199)
30. Frace A. M., Klimov A. I., Rowe T., Black R. A., Katz J. M., Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 1999 17 18 2237 2244 2-s2.0-0033522471 10.1016/S0264-410X(99)00005-5 (Pubitemid 29225675)
31. Mozdzanowska K., Feng J., Eid M., Kragol G., Cudic M., Otvos L. Jr., Gerhard W., Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003 21 19-20 2616 2626 2-s2.0-0038402706 10.1016/S0264-410X(03)00040-9 (Pubitemid 36561354)
32. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W. M., Fiers W., A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nature Medicine 1999 5 10 1157 1163 2-s2.0-0032874490 10.1038/13484 (Pubitemid 29474420)
33. Holo H., Nes I. F., High-frequency transformation, by electroporation, of Lactococcus lactis subsp. cremoris grown with glycine in osmotically stabilized media. Applied and Environmental Microbiology 1989 55 12 3119 3123 2-s2.0-0024345189 (Pubitemid 20002122)
34. Walsh P. M., McKay L. L., Recombinant plasmid associated with cell aggregation and high-frequency conjugation of Streptococcus lactis ML3. Journal of Bacteriology 1981 146 3 937 944 2-s2.0-0019452225 (Pubitemid 11048854)
35. Ausubel F. M., Brent R., Kingston R. E., Moore D. D., Seidman J. G., Smith J. A., Struhl K., Current Protocols in Molecular Biology 1998 New York, NY, USA John Wiley & Sons
36. Donald H. B., Isaacs A., Counts of influenza virus particles. Journal of General Microbiology 1954 10 3 457 464 2-s2.0-0001658090
37. Swayne D. E., Senne D. A., Beard C. W., A Laboratory Manual for the Isolation and Identification of Avian Pathogens 1998 Kennett Square, Pa, USA American Association of Avian Pathologists
38. Sitz K., Birx D., Lymphocyte proliferation assay. Methods in Molecular Medicine 1999 17 343 353
39. Grandea A. G. III, Olsen O. A., Cox T. C., Renshaw M., Hammond P. W., Chan-Hui P. Y., Mitcham J. L., Cieplak W., Stewart S. M., Grantham M. L., Pekosz A., Kiso M., Shinya K., Hatta M., Kawaoka Y., Moyle M., Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proceedings of the National Academy of Sciences of the United States of America 2010 107 28 12658 12663 2-s2.0-77955434077 10.1073/pnas.0911806107
40. Zharikova D., Mozdzanowska K., Feng J., Zhang M., Gerhard W., Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. Journal of Virology 2005 79 11 6644 6654 2-s2.0-18744377200 10.1128/JVI.79.11.6644-6654.2005 (Pubitemid 40677295)
41. Gerhard W., Mozdzanowska K., Zharikova D., Prospects for universal influenza virus vaccine. Emerging Infectious Diseases 2006 12 4 569 574 2-s2.0-33645470260
42. Lei H., Sheng Z., Ding Q., Chen J., Wei X., Lam D. M. K., Xu Y., Evaluation of oral immunization with recombinant avian influenza virus HA1 displayed on the Lactococcus lactis surface and combined with the mucosal adjuvant cholera toxin subunit B. Clinical and Vaccine Immunology 2011 18 7 1046 1051 2-s2.0-79960120764 10.1128/CVI.00050-11
43. Li Y. J., Ma G. P., Li G. W., Qiao X. Y., Ge J. W., Tang L. J., Liu M., Liu L. W., Oral vaccination with the porcine rotavirus VP4 outer capsid protein expressed by Lactococcus lactis induces specific antibody production. Journal of Biomedicine and Biotechnology 2010 2010 9 2-s2.0-77954553668 10.1155/2010/708460 708460
44. Bessa J., Schmitz N., Hinton H. J., Schwarz K., Jegerlehner A., Bachmann M. F., Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. European Journal of Immunology 2008 38 1 114 126 2-s2.0-38349049469 10.1002/eji.200636959
45. Denis J., Acosta-Ramirez E., Zhao Y., Hamelin M. E., Koukavica I., Baz M., Abed Y., Savard C., Pare C., Lopez Macias C., Boivin G., Leclerc D., Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 2008 26 27-28 3395 3403 2-s2.0-44749090233 10.1016/j.vaccine.2008.04.052
46. Mozdzanowska K., Zharikova D., Cudic M., Otvos L., Gerhard W., Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virology Journal 2007 4 118 131 2-s2.0-38049063865 10.1186/1743-422X-4-118
47. Eliasson D. G., El Bakkouri K., Schön K., Ramne A., Festjens E., Löwenadler B., Fiers W., Saelens X., Lycke N., CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 2008 26 9 1243 1252 2-s2.0-39149131018 10.1016/j.vaccine.2007.12.027
48. + T-cell activities that enhance the therapeutic activity of antiviral antibodies. Journal of Virology 2005 79 10 5943 5951 2-s2.0-18144413066 10.1128/JVI.79.10.5943-5951.2005 (Pubitemid 40617200)
49. Jegerlehner A., Schmitz N., Storni T., Bachmann M. F., Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. Journal of Immunology 2004 172 9 5598 5605 2-s2.0-2142810269 (Pubitemid 38542062)
50. Tompkins S. M., Zhao Z. S., Lo C. Y., Misplon J. A., Liu T., Ye Z., Hogan R. J., Wu Z., Benton K. A., Tumpey T. M., Epstein S. L., Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerging Infectious Diseases 2007 13 3 426 435 2-s2.0-33847348999 (Pubitemid 46348126)
51. Wang R., Song A., Levin J., Dennis D., Zhang N. J., Yoshida H., Koriazova L., Madura L., Shapiro L., Matsumoto A., Yoshida H., Mikayama T., Kubo R. T., Sarawar S., Cheroutre H., Kato S., Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Research 2008 80 2 168 177 2-s2.0-53249123060 10.1016/j.antiviral.2008.06.002
52. El Bakkouri K., Descamps F., de Filette M., Smet A., Festjens E., Birkett A., Van Rooijen N., Verbeek S., Fiers W., Saelens X., Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. Journal of Immunology 2011 186 2 1022 1031 2-s2.0-79251585956 10.4049/jimmunol.0902147